CN103908468A - 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 - Google Patents
环二核苷酸cGAMP在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN103908468A CN103908468A CN201410158564.8A CN201410158564A CN103908468A CN 103908468 A CN103908468 A CN 103908468A CN 201410158564 A CN201410158564 A CN 201410158564A CN 103908468 A CN103908468 A CN 103908468A
- Authority
- CN
- China
- Prior art keywords
- cgamp
- tumor
- human
- cell line
- preparing anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410158564.8A CN103908468B (zh) | 2014-04-21 | 2014-04-21 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
JP2016563423A JP2017513869A (ja) | 2014-04-21 | 2015-04-20 | 抗腫瘍における環状ジヌクレオチドcGAMPの応用 |
US15/304,924 US10092592B2 (en) | 2014-04-21 | 2015-04-20 | Application of cyclic dinucleotide (cGAMP) in anti-tumor field |
EP15783435.9A EP3135290B1 (en) | 2014-04-21 | 2015-04-20 | Antitumor use of cyclic dinucleotide cgamp |
PCT/CN2015/076961 WO2015161762A1 (zh) | 2014-04-21 | 2015-04-20 | 环二核苷酸cGAMP在抗肿瘤中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410158564.8A CN103908468B (zh) | 2014-04-21 | 2014-04-21 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908468A true CN103908468A (zh) | 2014-07-09 |
CN103908468B CN103908468B (zh) | 2017-02-08 |
Family
ID=51034672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410158564.8A Active CN103908468B (zh) | 2014-04-21 | 2014-04-21 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10092592B2 (zh) |
EP (1) | EP3135290B1 (zh) |
JP (1) | JP2017513869A (zh) |
CN (1) | CN103908468B (zh) |
WO (1) | WO2015161762A1 (zh) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015161762A1 (zh) * | 2014-04-21 | 2015-10-29 | 复旦大学 | 环二核苷酸cGAMP在抗肿瘤中的应用 |
WO2016096577A1 (en) * | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
WO2016100261A3 (en) * | 2014-12-17 | 2016-08-18 | Lipogen Llc | Method of treating cancer with cgamp or cgasmp |
CN106190999A (zh) * | 2015-05-10 | 2016-12-07 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP的高效制备方法 |
CN106236767A (zh) * | 2015-06-14 | 2016-12-21 | 聊城市奥润生物医药科技有限公司 | cGAMP在制备防治缺血性脑血管疾病药物中的应用 |
CN106267213A (zh) * | 2015-05-27 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
CN106265716A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗糖尿病中的应用 |
CN106265714A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在制备抗病毒药物中的应用 |
CN106265715A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在制备保健品中的应用 |
CN106309484A (zh) * | 2015-07-02 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | 硫(硒)代磷酸环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
CN106309467A (zh) * | 2015-06-14 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP用于制备治疗颅脑创伤及其后遗症产品中的用途 |
CN106442992A (zh) * | 2016-08-03 | 2017-02-22 | 上海延安药业有限公司 | 阿比特龙衍生物的药代动力学评估方法 |
WO2017045595A1 (zh) * | 2015-09-18 | 2017-03-23 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 |
CN106539815A (zh) * | 2016-01-21 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸在防治多发性硬化症中的应用 |
CN106539814A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗类风湿性关节炎等疾病中的应用 |
CN106539812A (zh) * | 2015-11-18 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在抗结直肠癌肝转移中的应用 |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
CN106539811A (zh) * | 2016-01-16 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在防治抗肿瘤化药诱发的并发症或降低化疗药诱导的毒副作用中的应用 |
WO2017062838A1 (en) | 2015-10-07 | 2017-04-13 | Nant Holdings Ip, Llc | Activation of immune-related signalling pathways in cells via optofection |
CN106692967A (zh) * | 2015-08-12 | 2017-05-24 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合PD1的抗体(Nivolumab)在制备抗肿瘤药物中的应用 |
CN106727331A (zh) * | 2017-03-13 | 2017-05-31 | 聊城市奥润生物医药科技有限公司 | 免疫脂质体‑环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
WO2017096963A1 (zh) * | 2015-12-09 | 2017-06-15 | 聊城市奥润生物医药科技有限公司 | 干扰素刺激基因(sting)激动剂在治疗阿尔茨海默症中的应用 |
US10011630B2 (en) | 2014-12-16 | 2018-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
CN108892700A (zh) * | 2018-05-27 | 2018-11-27 | 杭州星鳌生物科技有限公司 | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 |
CN110461334A (zh) * | 2016-12-22 | 2019-11-15 | 马福制药公司 | 增强或增加i型ifn产生的组合物和方法 |
CN111138508A (zh) * | 2018-11-02 | 2020-05-12 | 杭州星鳌生物科技有限公司 | 创新环二核苷酸金属配合物的合成及其在抗肿瘤药物中的应用 |
CN111714616A (zh) * | 2019-07-17 | 2020-09-29 | 江苏西宏生物医药有限公司 | 一种用于抗肿瘤的组合物 |
WO2022228469A1 (zh) * | 2021-04-28 | 2022-11-03 | 苏州大学 | 聚合物囊泡纳米sting激动剂及其制备方法与应用 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170015353A (ko) | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조절제로서 사이클릭 디뉴클레오타이드 |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
MX2018001814A (es) | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
PE20181297A1 (es) | 2015-12-03 | 2018-08-07 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purino ciclico como moduladores de sting |
CN109475570B (zh) | 2016-03-18 | 2022-04-01 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
LT3523287T (lt) | 2016-10-04 | 2021-11-10 | Merck Sharp & Dohme Corp. | Benzo[b]tiofeno junginiai, kaip sting agonistai |
EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS |
JP7326319B2 (ja) | 2018-04-03 | 2023-08-15 | メルク・シャープ・アンド・ドーム・エルエルシー | Stingアゴニストとしてのベンゾチオフェン類及び関連する化合物 |
US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
CN108653312B (zh) * | 2018-04-28 | 2020-05-19 | 杭州星鳌生物科技有限公司 | 内质网受体蛋白sting的激活剂联合磷酸二酯酶enpp1的抑制剂抗肿瘤研究 |
US20210380695A1 (en) | 2020-05-15 | 2021-12-09 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with immune checkpoint inhibitors |
US20230121320A1 (en) | 2021-07-23 | 2023-04-20 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102199183A (zh) * | 2010-03-26 | 2011-09-28 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
WO2013185052A1 (en) * | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
CN105008381A (zh) * | 2012-12-13 | 2015-10-28 | 艾杜罗生物科技公司 | 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
EP1729781B1 (en) * | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
WO2012117323A1 (en) * | 2011-02-28 | 2012-09-07 | Cadila Pharmaceuticals Limited | Therapeutic cancer vaccine |
CN103908468B (zh) * | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
-
2014
- 2014-04-21 CN CN201410158564.8A patent/CN103908468B/zh active Active
-
2015
- 2015-04-20 JP JP2016563423A patent/JP2017513869A/ja active Pending
- 2015-04-20 EP EP15783435.9A patent/EP3135290B1/en active Active
- 2015-04-20 WO PCT/CN2015/076961 patent/WO2015161762A1/zh active Application Filing
- 2015-04-20 US US15/304,924 patent/US10092592B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102199183A (zh) * | 2010-03-26 | 2011-09-28 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
WO2013185052A1 (en) * | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
CN104507538A (zh) * | 2012-06-08 | 2015-04-08 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
CN105008381A (zh) * | 2012-12-13 | 2015-10-28 | 艾杜罗生物科技公司 | 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法 |
Non-Patent Citations (3)
Title |
---|
JIAXI WU: "Cyclic-GMP-AMP Is An Endogenous Second Messenger inInnate Immune Signaling by Cytosolic DNA", 《SCIENCE》 * |
LIJUN SUN: "Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor thatActivates the Type-I Interferon Pathway", 《SCIENCE》 * |
XIAO-DONG LI: "Pivotal Roles of cGAS-cGAMPSignaling in Antiviral Defense andImmune Adjuvant Effects", 《SCIENCE》 * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015161762A1 (zh) * | 2014-04-21 | 2015-10-29 | 复旦大学 | 环二核苷酸cGAMP在抗肿瘤中的应用 |
WO2016096577A1 (en) * | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
US11053272B2 (en) | 2014-12-16 | 2021-07-06 | Kayla Therapeutics | Cyclic dinucleotides for cytokine induction |
US11667664B2 (en) | 2014-12-16 | 2023-06-06 | Kayla Therapeutics | Cyclic dinucleotides for cytokine induction |
US10011630B2 (en) | 2014-12-16 | 2018-07-03 | Invivogen | Cyclic dinucleotides for cytokine induction |
US10562929B2 (en) | 2014-12-16 | 2020-02-18 | Kayla Therapeutics | Cyclic dinucleotides for cytokine induction |
WO2016100261A3 (en) * | 2014-12-17 | 2016-08-18 | Lipogen Llc | Method of treating cancer with cgamp or cgasmp |
AU2015362773B2 (en) * | 2014-12-17 | 2019-01-03 | Lipogen Llc | Method of treating cancer with cGAMP or cGAsMP |
CN107106589A (zh) * | 2014-12-17 | 2017-08-29 | 立博美华基因科技有限责任公司 | 用cGAMP或cGAsMP治疗癌症的方法 |
CN106190999A (zh) * | 2015-05-10 | 2016-12-07 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP的高效制备方法 |
CN106265715A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在制备保健品中的应用 |
CN106265716A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗糖尿病中的应用 |
CN106265715B (zh) * | 2015-05-19 | 2020-02-07 | 杭州星鳌生物科技有限公司 | 环二核苷酸cGAMP在制备防老年痴呆药物中的应用 |
CN106265714A (zh) * | 2015-05-19 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在制备抗病毒药物中的应用 |
CN106267213A (zh) * | 2015-05-27 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
CN106309467A (zh) * | 2015-06-14 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP用于制备治疗颅脑创伤及其后遗症产品中的用途 |
CN106236767A (zh) * | 2015-06-14 | 2016-12-21 | 聊城市奥润生物医药科技有限公司 | cGAMP在制备防治缺血性脑血管疾病药物中的应用 |
CN106309467B (zh) * | 2015-06-14 | 2020-01-17 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP用于制备治疗颅脑创伤及其后遗症产品中的用途 |
CN106309484A (zh) * | 2015-07-02 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | 硫(硒)代磷酸环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
CN106692967A (zh) * | 2015-08-12 | 2017-05-24 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合PD1的抗体(Nivolumab)在制备抗肿瘤药物中的应用 |
WO2017045595A1 (zh) * | 2015-09-18 | 2017-03-23 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 |
WO2017062838A1 (en) | 2015-10-07 | 2017-04-13 | Nant Holdings Ip, Llc | Activation of immune-related signalling pathways in cells via optofection |
US10322177B2 (en) | 2015-10-07 | 2019-06-18 | Nant Holdings Ip, Llc | Activation of immune-related signaling pathways in cells via optofection |
CN106539812B (zh) * | 2015-11-18 | 2019-12-03 | 杭州星鳌生物科技有限公司 | 环二核苷酸cGAMP在抗结直肠癌肝转移中的应用 |
CN106539812A (zh) * | 2015-11-18 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在抗结直肠癌肝转移中的应用 |
WO2017096963A1 (zh) * | 2015-12-09 | 2017-06-15 | 聊城市奥润生物医药科技有限公司 | 干扰素刺激基因(sting)激动剂在治疗阿尔茨海默症中的应用 |
CN106539814A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白(sting)激动剂在抗类风湿性关节炎等疾病中的应用 |
CN106539811A (zh) * | 2016-01-16 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在防治抗肿瘤化药诱发的并发症或降低化疗药诱导的毒副作用中的应用 |
CN106539811B (zh) * | 2016-01-16 | 2019-12-20 | 杭州星鳌生物科技有限公司 | 环二核苷酸cGAMP在防治抗肿瘤化药诱发的并发症或降低化疗药诱导的毒副作用中的应用 |
CN106539815B (zh) * | 2016-01-21 | 2019-12-03 | 杭州星鳌生物科技有限公司 | 环二核苷酸在防治多发性硬化症中的应用 |
CN106539815A (zh) * | 2016-01-21 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸在防治多发性硬化症中的应用 |
CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
CN106442992A (zh) * | 2016-08-03 | 2017-02-22 | 上海延安药业有限公司 | 阿比特龙衍生物的药代动力学评估方法 |
CN110461334A (zh) * | 2016-12-22 | 2019-11-15 | 马福制药公司 | 增强或增加i型ifn产生的组合物和方法 |
CN106727331A (zh) * | 2017-03-13 | 2017-05-31 | 聊城市奥润生物医药科技有限公司 | 免疫脂质体‑环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
CN106727331B (zh) * | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
CN108892700B (zh) * | 2018-05-27 | 2020-07-07 | 杭州星鳌生物科技有限公司 | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 |
WO2019228286A1 (zh) * | 2018-05-27 | 2019-12-05 | 杭州星鳌生物科技有限公司 | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 |
CN108892700A (zh) * | 2018-05-27 | 2018-11-27 | 杭州星鳌生物科技有限公司 | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 |
CN111138508A (zh) * | 2018-11-02 | 2020-05-12 | 杭州星鳌生物科技有限公司 | 创新环二核苷酸金属配合物的合成及其在抗肿瘤药物中的应用 |
CN111714616A (zh) * | 2019-07-17 | 2020-09-29 | 江苏西宏生物医药有限公司 | 一种用于抗肿瘤的组合物 |
WO2022228469A1 (zh) * | 2021-04-28 | 2022-11-03 | 苏州大学 | 聚合物囊泡纳米sting激动剂及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3135290A1 (en) | 2017-03-01 |
US20170196902A1 (en) | 2017-07-13 |
EP3135290A4 (en) | 2018-01-03 |
CN103908468B (zh) | 2017-02-08 |
US10092592B2 (en) | 2018-10-09 |
EP3135290B1 (en) | 2019-06-12 |
WO2015161762A1 (zh) | 2015-10-29 |
JP2017513869A (ja) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103908468B (zh) | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 | |
CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
CN106539757A (zh) | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 | |
CN102617610A (zh) | 卟啉类光敏剂与抗癌药二联体的制备方法 | |
CN106552265A (zh) | Sting激动剂与ido1抑制剂联合用药在抗肿瘤中的应用 | |
CN108892700B (zh) | 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用 | |
CN107438437A (zh) | 用于癌症的新治疗 | |
WO2006137398A1 (ja) | 癌治療薬 | |
CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
JP2018513130A (ja) | Hsp90阻害ペプチド結合体及びその腫瘍治療における応用 | |
CN108410878B (zh) | 一种lrpprc特异性核酸适配体及其应用 | |
CN106631957A (zh) | 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用 | |
CN111420025B (zh) | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 | |
CN108653312A (zh) | 内质网受体蛋白sting的激活剂联合磷酸二酯酶enpp1的抑制剂抗肿瘤研究 | |
CN104557909A (zh) | 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途 | |
CN106928298B (zh) | 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用 | |
US20240238434A1 (en) | Use of medicament in treatment of tumor disease | |
CN113329745A (zh) | 一种有效抗恶性肿瘤的药物组合物及其应用 | |
CN105435241A (zh) | 一种iRGD-抗癌药物偶联物及其制备方法和应用 | |
CN106540255A (zh) | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 | |
CN106692967A (zh) | 环二核苷酸cGAMP联合PD1的抗体(Nivolumab)在制备抗肿瘤药物中的应用 | |
CN115590944A (zh) | Rkc-b1在治疗肺癌方面的用途 | |
US10335427B2 (en) | Tumor prevention and treatment drug and applications thereof | |
Fialho et al. | Recent patents on bacterial proteins as potential anticancer agents | |
CN105193810B (zh) | 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160909 Address after: 200235, room six, building 333, 218 Guiping Road, Shanghai, Xuhui District Applicant after: SHANGHAI BAJIAYI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant after: LIAOCHENG CITY ORIENT BIOMEDICAL TECHNOLOGY Co.,Ltd. Address before: 200235, room six, building 333, 218 Guiping Road, Shanghai, Xuhui District Applicant before: SHANGHAI BAJIAYI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Effective date of registration: 20160909 Address after: 200235, room six, building 333, 218 Guiping Road, Shanghai, Xuhui District Applicant after: SHANGHAI BAJIAYI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 200433 Handan Road, Shanghai, No. 220, No. Applicant before: Fudan University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |